Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 9Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 52Neoplasms 36Colorectal Neoplasms 33Prostatic Neoplasms 31Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 30Pancreatic Neoplasms 21Multiple Myeloma 16Recurrence 14Ovarian Neoplasms 14Uterine Cervical Neoplasms 12Leukemia, Myeloid, Acute 11Carcinoma, Hepatocellular 11Neoplasm Metastasis 10Head and Neck Neoplasms 10Brain Neoplasms 10Melanoma 9Stomach Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Rectal Neoplasms 8Advanced Solid Tumors 8Triple Negative Breast Neoplasms 7Small Cell Lung Carcinoma 7Glioblastoma 7Endometrial Neoplasms 7Carcinoma, Renal Cell 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Glioma 6Esophageal Neoplasms 6Colonic Neoplasms 6

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Merkel Cell × 30 days × Clear all
NCT07472322 2026-05-29

ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1

University of Wisconsin, Madison

Phase 1/2 Not yet recruiting
31 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡